Vitamin D supplementation in pre-dialysis chronic kidney disease: A systematic review

Dermato-Endocrinology

Volumn 4, Issue 2, 2012, Pages 118-127

  Alvarez, Jessica A ^a   Wasse, Haimanot ^a   Tangpricha, Vin ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cholecalciferol; Chronic kidney disease; Ergocalciferol; Renal disease; Secondary hyperparathyroidism; Vitamin D

Indexed keywords

COLECALCIFEROL; CREATININE; ERGOCALCIFEROL; PARATHYROID HORMONE;

BONE METABOLISM; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMPARATIVE EFFECTIVENESS; CREATININE BLOOD LEVEL; DIALYSIS; DISEASE COURSE; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; IMMUNITY; INFLAMMATION; MORTALITY; OXIDATIVE STRESS; PARATHYROID HORMONE BLOOD LEVEL; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION;

EID: 84865195958     PISSN: 19381972     EISSN: 19381980     Source Type: Journal    
DOI: 10.4161/derm.20014     Document Type: Review

References (93)

1. Castro AF, Coresh J. CKD surveillance using laboratory data from the population-based National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 2009; 53(Suppl 3):S46-55; PMID: 19231761; http://dx.doi.org/10.1053/ j.ajkd.2008.07.054
2. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (Suppl 3):S1-201; PMID:14520607; http://dx.doi.org/10.1016/S0272-6386(03)00553-5
3. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int 2011; 80:1258-70; PMID:21993585; http://dx.doi.org/10.1038/ki.2011.368
4. Judd SE, Tangpricha V. Vitamin d therapy and cardiovascular health. Curr Hypertens Rep 2011; 13:187-91; PMID:21298577; http://dx.doi.org/10.1007/s11906- 011-0190-2
5. Kamen DL, Tangpricha V. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. J Mol Med (Berl) 2010; 88:441-50; PMID:20119827; http://dx.doi.org/10.1007/s00109-010-0590-9
6. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis 2011; 58:374-82; PMID:21636193
7. Tebben PK, Vitamin R. D and the Kidney. In: Feldman DP, J.W.; Adams, J.S., ed. Vitamin D. Amsterdam: Elsevier Inc, 2011:471-91.
8. Dusso ASS. E. Vitamin D and Renal Disease. In: Feldman DP, J.W.; Adams, J.S., ed. Vitamin D. Amsterdam: Elsevier Inc, 2011:1325-57.
9. Jones G. Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D (3). Semin Dial 2007; 20:316-24; PMID:17635821; http://dx.doi.org/10.1111/j.1525-139X.2007. 00302.x
10. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16:2205-15; PMID:15917335; http://dx.doi.org/10.1681/ASN.2005010052
11. Perwad F, Zhang MY, Tenenhouse HS, Portale AA. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 2007; 293:F1577-83; PMID:17699549; http://dx.doi.org/10.1152/ajprenal. 00463.2006
12. Usatii M, Rousseau L, Demers C, Petit JL, Brossard JH, Gascon-Barré M, et al. Parathyroid hormone fragments inhibit active hormone and hypocalcemia-induced 1,25(OH)2D synthesis. Kidney Int 2007; 72:1330-5; PMID:17805236; http://dx.doi.org/10.1038/sj.ki.5002532
13. Hsu CH, Patel S. Uremic plasma contains factors inhibiting 1 alpha-hydroxylase activity. J Am Soc Nephrol 1992; 3:947-52; PMID:1450371
14. Kalantar-Zadeh K, Kovesdy CP. Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4:1529-39; PMID:19661219; http://dx.doi.org/10.2215/CJN.02140309
15. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, et al. Evidence for persistent vitamin D 1-alpha-hydroxylation in hemodialysis patients: evolution of serum 1,25-dihydroxycholecalciferol after 6 months of 25-hydroxycholecalciferol treatment. Nephron Clin Pract 2008; 110:c58-65; PMID: 18724068; http://dx.doi.org/10.1159/000151534
16. Wasse H, Huang R, Long Q, Singapuri S, Raggi P, Tangpricha V. Efficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis. Am J Clin Nutr 2012; 95:522-8; PMID:22237061; http://dx.doi.org/10.3945/ajcn. 111.025502
17. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-81; PMID:17634462; http://dx.doi.org/10.1056/NEJMra070553
18. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:1911-30; PMID:21646368; http://dx.doi.org/10.1210/jc.2011-0385
19. LaClair RE, Hellman RN, Karp SL, Kraus M, Ofner S, Li Q, et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 2005; 45:1026-33; PMID: 15957131; http://dx.doi.org/10.1053/j.ajkd.2005.02.029
20. Mehrotra R, Kermah D, Budoff M, Salusky IB, Mao SS, Gao YL, et al. Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol 2008; 3:1144-51; PMID:18417740; http://dx.doi.org/10.2215/CJN.05781207
21. Robinson AB, Thierry-Palmer M, Gibson KL, Rabinovich CE. Disease activity, proteinuria, and vitamin D status in children with systemic lupus erythematosus and juvenile dermatomyositis. J Pediatr 2012; 160:297-302; PMID:21924736; http://dx.doi.org/10.1016/j.jpeds.2011.08.011
22. Dusso AS, Tokumoto M. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. Kidney Int 2011; 79:715-29; PMID:21270766; http://dx.doi.org/10.1038/ ki.2010.543
23. Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C, Herz J, et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999; 96:507-15; PMID:10052453; http://dx.doi.org/10. 1016/S0092-8674(00)80655-8
24. Chonchol M, Kendrick J, Targher G. Extra-skeletal effects of vitamin D deficiency in chronic kidney disease. Ann Med 2011; 43:273-82; PMID:21214426; http://dx.doi.org/10.3109/07853890.2010.543923
25. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351:1296-305; PMID:15385656; http://dx.doi.org/10.1056/NEJMoa041031
26. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004; 15:1307-15; PMID:15100371; http://dx.doi.org/10.1097/01.ASN. 0000123691.46138.E2
27. Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Jain A, Schreiber MJ, Jr., et al. Low 25-hydroxyvitamin D levels and mortality in non-dialysis- dependent CKD. Am J Kidney Dis 2011; 58:536-43; PMID:21816525; http://dx.doi.org/10.1053/j.ajkd.2011.04.028
28. Zittermann A, Iodice S, Pilz S, Grant WB, Bagnardi V, Gandini S. Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. Am J Clin Nutr 2012; 95:91-100; PMID:22170374; http://dx.doi.org/10.3945/ajcn.111.014779
29. Chandra P, Binongo JN, Ziegler TR, Schlanger LE, Wang W, Someren JT, et al. Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract 2008; 14:10-7; PMID: 18238736
30. Shroff R, Wan M, Gullett A, Ledermann S, Shute R, Knott C, et al. Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial. Clin J Am Soc Nephrol 2012; 7:216-23; PMID:22266572; http://dx.doi.org/10.2215/CJN.04760511
31. Kovesdy CP, Lu JL, Malakauskas SM, Andress DL, Kalantar-Zadeh K, Ahmadzadeh S. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial. Am J Kidney Dis 2012; 59:58-66; PMID:21885174; http://dx.doi.org/10.1053/j.ajkd.2011. 06.027
32. Moe SM, Saifullah A, LaClair RE, Usman SA, Yu Z. A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease. Clin J Am Soc Nephrol 2010; 5:299-306; PMID:20056760; http://dx.doi.org/10.2215/CJN.07131009
33. Dogan E, Erkoc R, Sayarlioglu H, Soyoral Y, Dulger H. Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients. Ren Fail 2008; 30:407-10; PMID:18569914; http://dx.doi.org/10.1080/08860220801964210
34. Rucker D, Tonelli M, Coles MG, Yoo S, Young K, McMahon AW. Vitamin D insufficiency and treatment with oral vitamin D3 in northern-dwelling patients with chronic kidney disease. J Nephrol 2009; 22:75-82; PMID:19229821
35. Taner B, Abdulkadir U. Effect of cholecalciferol on parathyroid hormone and vitamin D levels in chronic kidney disease. Minerva Urol Nefrol 2011; 63:287-92; PMID:21996984
36. Oksa A, Spustová V, Krivosíková Z, Gazdíková K, Fedelesová V, Lajdová I, et al. Effects of long-term cholecalciferol supplementation on mineral metabolism and calciotropic hormones in chronic kidney disease. Kidney Blood Press Res 2008; 31:322-9; PMID: 18802363; http://dx.doi.org/10.1159/000157177
37. Hari P, Gupta N, Hari S, Gulati A, Mahajan P, Bagga A. Vitamin D insufficiency and effect of cholecalciferol in children with chronic kidney disease. Pediatr Nephrol 2010; 25:2483-8; PMID:20872152; http://dx.doi.org/10. 1007/s00467-010-1639-2
38. DeVille J, Thorp ML, Tobin L, Gray E, Johnson ES, Smith DH. Effect of ergocalciferol supplementation on serum parathyroid hormone and serum 25-hydroxyvitamin D in chronic kidney disease. Nephrology (Carlton) 2006; 11:555-9; PMID:17199797; http://dx.doi.org/10.1111/j.1440-1797.2006.00698.x
39. Trakarnvanich T, Chalapipat O, Disthabanchong S, Kurathong S, Praditpornsilpa K, Stitchantrakul W, et al. Effect of high dose ergocalciferol in chronic kidney disease patients with 25-hydroxyvitamin D deficiency. J Med Assoc Thai 2010; 93:885-91; PMID:20718162
40. Zisman AL, Hristova M, Ho LT, Sprague SM. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 2007; 27:36-43; PMID: 17215573; http://dx.doi.org/10.1159/000098561
41. Lishmanov A, Dorairajan S, Pak Y, Chaudhary K, Chockalingam A. Treatment of 25-OH Vitamin D Deficiency in Older Men With Chronic Kidney Disease Stages 3 and 4 Is Associated With Reduction in Cardiovascular Events. Am J Ther 2011; PMID:22185755; http://dx.doi.org/10.1097/MJT.0b013e3182211b3b
42. Al-Aly Z, Qazi RA, González EA, Zeringue A, Martin KJ. Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis 2007; 50:59-68; PMID:17591525; http://dx.doi.org/10.1053/j.ajkd.2007.04.010
43. Menon S, Valentini RP, Hidalgo G, Peschansky L, Mattoo TK. Vitamin D insufficiency and hyperparathyroidism in children with chronic kidney disease. Pediatr Nephrol 2008; 23:1831-6; PMID:18575896; http://dx.doi.org/10.1007/ s00467-008-0842-x
44. Qunibi WY, Abdellatif A, Sankar S, Hamdan Z, Lin FY, Ingle J, et al. Treatment of vitamin D deficiency in CKD patients with ergocalciferol: are current K/DOQI treatment guidelines adequate? Clin Nephrol 2010; 73:276-85; PMID:20353735
45. Lajdova I, Spustova V, Oksa A, Chorvatova A, Chorvat D, Jr., Dzurik R. Intracellular calcium homeostasis in patients with early stages of chronic kidney disease: effects of vitamin D3 supplementation. Nephrol Dial Transplant 2009; 24:3376-81; PMID:19531669; http://dx.doi.org/10.1093/ndt/gfp292
46. Shroff R, Wan M, Rees L. Can vitamin D slow down the progression of chronic kidney disease? Pediatr Nephrol 2011; PMID:22160397; http://dx.doi.org/10.1007/s00467-011-2071-y
47. Mehrotra R, Kermah DA, Salusky IB, Wolf MS, Thadhani RI, Chiu YW, et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int 2009; 76:977-83; PMID:19657329; http://dx.doi.org/10.1038/ki.2009.288
48. Melamed ML, Astor B, Michos ED, Hostetter TH, Powe NR, Muntner P. 25-hydroxyvitamin D levels, race, and the progression of kidney disease. J Am Soc Nephrol 2009; 20:2631-9; PMID:19875805; http://dx.doi.org/10.1681/ASN. 2009030283
49. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009; 75:88-95; PMID:18843258; http://dx.doi.org/10.1038/ki.2008.501
50. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004; 89:5387-91; PMID: 15531486; http://dx.doi.org/10.1210/jc.2004-0360
51. Heaney RP, Recker RR, Grote J, Horst RL, Armas LA. Vitamin D(3) is more potent than vitamin D(2) in humans. J Clin Endocrinol Metab 2011; 96:E447-52; PMID:21177785; http://dx.doi.org/10.1210/jc.2010-2230
52. Trang HM, Cole DE, Rubin LA, Pierratos A, Siu S, Vieth R. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr 1998; 68:854-8; PMID:9771862
53. Kandula P, Dobre M, Schold JD, Schreiber MJ, Jr., Mehrotra R, Navaneethan SD. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 2011; 6:50-62; PMID:20876671; http://dx.doi.org/10.2215/ CJN.03940510
54. Repo JM, Rantala IS, Honkanen TT, Mustonen JT, Kööbi P, Tahvanainen AM, et al. Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol. Kidney Int 2007; 72:977-84; PMID: 17667981; http://dx.doi.org/10.1038/sj.ki.5002458
55. Ritter CS, Armbrecht HJ, Slatopolsky E, Brown AJ. 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int 2006; 70:654-9; PMID:16807549; http://dx.doi.org/10.1038/sj.ki.5000394
56. Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, et al. Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int 2011; 79:1331-40; PMID: 21289598; http://dx.doi.org/10.1038/ki.2010.550
57. Menon V, Greene T, Wang X, Pereira AA, Marcovina SM, Beck GJ, et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68:766-72; PMID:16014054
58. de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007; 50:69-77; PMID:17591526; http://dx.doi.org/10.1053/j.ajkd.2007.04.015
59. Isakova T, Gutiérrez OM, Patel NM, Andress DL, Wolf M, Levin A. Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions. J Ren Nutr 2011; 21:295-302; PMID: 20817560; http://dx.doi.org/10.1053/j.jrn.2010.07.002
60. Li YC. Vitamin D: roles in renal and cardiovascular protection. Curr Opin Nephrol Hypertens 2012; 21:72-9; PMID:22143249; http://dx.doi.org/10.1097/MNH. 0b013e32834de4ee
61. Dusso A, Arcidiacono MV, Yang J, Tokumoto M. Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality. J Steroid Biochem Mol Biol 2010; 121:193-8; PMID: 20359533; http://dx.doi.org/10.1016/j. jsbmb.2010.03.064
62. Melenhorst WB, Visser L, Timmer A, van den Heuvel MC, Stegeman CA, van Goor H. ADAM17 upregulation in human renal disease: a role in modulating TGF-alpha availability? Am J Physiol Renal Physiol 2009; 297:F781-90; PMID:19535569; http://dx.doi.org/10.1152/ajprenal.90610.2008
63. Deb DK, Wang Y, Zhang Z, Nie H, Huang X, Yuan Z, et al. Molecular mechanism underlying 1,25-dihydroxyvitamin D regulation of nephrin gene expression. J Biol Chem 2011; 286:32011-7; PMID:21803771; http://dx.doi.org/10. 1074/jbc.M111.269118
64. Liu W, Yu WR, Carling T, Juhlin C, Rastad J, Ridefelt P, et al. Regulation of gp330/megalin expression by vitamins A and D. Eur J Clin Invest 1998; 28:100-7; PMID:9541123; http://dx.doi.org/10.1046/j.1365-2362.1998.00253.x
65. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68:2823-8; PMID:16316359; http://dx.doi.org/10.1111/j.1523-1755.2005. 00755.x
66. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008; 52:249-55; PMID:18606901; http://dx.doi.org/10.1161/HYPERTENSIONAHA.108.113159
67. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376:1543-51; PMID:21055801; http://dx.doi.org/10. 1016/S0140-6736(10)61032-X
68. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009; 54:647-52; PMID:19596163; http://dx.doi.org/10. 1053/j.ajkd.2009.04.036
69. Weir MR. Short-term effects of vitamin D receptor activation on serum creatinine, creatinine generation, and glomerular filtration. Kidney Int 2011; 80:1016-7; PMID:22042029; http://dx.doi.org/10.1038/ki.2011.265
70. Kalantar-Zadeh K, Cano NJ, Budde K, Chazot C, Kovesdy CP, Mak RH, et al. Diets and enteral supplements for improving outcomes in chronic kidney disease. Nat Rev Nephrol 2011; 7:369-84; PMID: 21629229; http://dx.doi.org/10.1038/ nrneph.2011.60
71. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008; 19:1613-9; PMID:18463168; http://dx.doi.org/10.1681/ASN.2007111164
72. Wang HE, Gamboa C, Warnock DG, Muntner P. Chronic kidney disease and risk of death from infection. Am J Nephrol 2011; 34:330-6; PMID:21860228; http://dx.doi.org/10.1159/000330673
73. Fabri M, Stenger S, Shin DM, Yuk JM, Liu PT, Realegeno S, et al. Vitamin D is required for IFN-gamma-mediated antimicrobial activity of human macrophages. Sci Transl Med 2011; 3:ra102; PMID: 21998409; http://dx.doi.org/10. 1126/scitranslmed.3003045
74. Hübel E, Kiefer T, Weber J, Mettang T, Kuhlmann U. In vivo effect of 1,25-dihydroxyvitamin D3 on phagocyte function in hemodialysis patients. Kidney Int 1991; 40:927-33; PMID:1662316; http://dx.doi.org/10.1038/ki.1991.296
75. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311:1770-3; PMID:16497887; http://dx.doi.org/10.1126/science. 1123933
76. Drechsler C, Pilz S, Obermayer-Pietsch B, Verduijn M, Tomaschitz A, Krane V, et al. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J 2010; 31:2253-61; PMID:20688781; http://dx.doi.org/10.1093/eurheartj/ ehq246
77. Wang AY, Lam CW, Sanderson JE, Wang M, Chan IH, Lui SF, et al. Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. Am J Clin Nutr 2008; 87:1631-8; PMID:18541550
78. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GF. Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 2007; 147:840-53; PMID:18087055
79. Kim HW, Park CW, Shin YS, Kim YS, Shin SJ, Kim YS, et al. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clin Pract 2006; 102:c21-9; PMID:16166802; http://dx.doi.org/10.1159/000088295
80. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110:229-38; PMID:12122115
81. Petchey WG, Johnson DW, Isbel NM. Shining D'light on chronic kidney disease: mechanisms that may underpin the cardiovascular benefit of vitamin D. Nephrology (Carlton) 2011; 16:351-67; PMID: 21323790; http://dx.doi.org/10.1111/ j.1440-1797.2011.01450.x
82. Alvarez JA, Ashraf A. Role of vitamin d in insulin secretion and insulin sensitivity for glucose homeostasis. Int J Endocrinol 2010; 2010:351385; PMID: 20011094; http://dx.doi.org/10.1155/2010/351385
83. Cohen-Lahav M, Shany S, Tobvin D, Chaimovitz C, Douvdevani A. Vitamin D decreases NFkappaB activity by increasing IkappaBalpha levels. Nephrol Dial Transplant 2006; 21:889-97; PMID:16455676; http://dx.doi.org/10.1093/ndt/gfi254
84. Talmor-Barkan Y, Bernheim J, Green J, Benchetrit S, Rashid G. Calcitriol counteracts endothelial cell proinflammatory processes in a chronic kidney disease-like environment. J Steroid Biochem Mol Biol 2011; 124:19-24; PMID:21236342; http://dx.doi.org/10.1016/j.jsbmb.2011.01.001
85. Tanaka M, Tokunaga K, Komaba H, Itoh K, Matsushita K, Watanabe H, et al. Vitamin D receptor activator reduces oxidative stress in hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial 2011; 15:161-8; PMID:21426509; http://dx.doi.org/10.1111/j.1744-9987.2010.00890.x
86. Günal AI, Celiker H, Celebi H, Ustündaǧ B, Günal SY. Intravenous alfacalcidol improves insulin resistance in hemodialysis patients. Clin Nephrol 1997; 48:109-13; PMID:9285148
87. Kautzky-Willer A, Pacini G, Barnas U, Ludvik B, Streli C, Graf H, et al. Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int 1995; 47:200-6; PMID:7731147; http://dx.doi.org/10.1038/ki.1995.24
88. Mak RH. Amelioration of hypertension and insulin resistance by 1,25-dihydroxycholecalciferol in hemodialysis patients. Pediatr Nephrol 1992; 6:345-8; PMID: 1498003; http://dx.doi.org/10.1007/BF00869730
89. Mak RH. Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int 1992; 41:1049-54; PMID:1513086; http://dx.doi.org/10.1038/ki.1992.159
90. Mak RH. 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int 1998; 53:1353-7; PMID:9573552; http://dx.doi.org/10.1046/ j.1523-1755.1998.00865.x
91. Matias PJ, Jorge C, Ferreira C, Borges M, Aires I, Amaral T, et al. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol 2010; 5:905-11; PMID:20203163; http://dx.doi.org/10.2215/CJN.06510909
92. Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999; 33:73-81; PMID:9915270; http://dx.doi.org/10.1016/S0272-6386(99)70260-X
93. Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD. Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 2010; 21:353-61; PMID:20007751; http://dx.doi.org/10.1681/ASN.2009040451